Irinotecan as single agent in the treatment of colorectal cancer: Results of phase II studies;L'irinotecan en monotherapie dans le traitement des cancers colorectaux: Resultats des etudes de phase II

Bulletin du Cancer

Volumn 85, Issue SPEC. ISS. DEC., 1998, Pages 33-37

  Van Cutsem, Éric ^a   Peeters, Marc ^a  

^a Hop Universitaire Gasthuisberg   (Belgium)

Author keywords

Chemotherapy; Colorectal cancer; Irinotecan

Indexed keywords

FLUOROURACIL; IRINOTECAN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; TUMOR PROTEIN;

ALOPECIA; ANOREXIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME; VOMITING; ADENOCARCINOMA; ADULT; AGED; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYMOLOGY; EUROPE; FEMALE; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; REMISSION; SALVAGE THERAPY; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CLINICAL TRIALS, PHASE II; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; EUROPE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PALLIATIVE CARE; REMISSION INDUCTION; SALVAGE THERAPY; TREATMENT OUTCOME; UNITED STATES;

EID: 0032240675     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer - a randomized trial. J Clin Oncol 1992 ; 10 : 904-11.
2. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993 ; 306 : 752-5.
3. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer - evidence in terms of response rate. J Clin Oncol 1992 ; 10 : 896-903.
4. Moore TD, Cole KE, Christian MC, Arbuck S. Trials of investigational drugs in colorectal cancer. In : Cohen AM, Winawer SJ, Friedman MA, Gunderson LL, eds. Cancer of the colon, rectum and anus. New York, NY, McGraw-Hill, 1995 ; 919-31.
5. Arbuck SG. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989 ; 63 : 1036-44.
6. Weh HJ, Wilke HJ, Dierlamm J, Klaassen U, Siegmund R, Illiger H, et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU), 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994 ; 5 : 233-7.
7. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu J, Brienza S, et al. Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996 ; 7 : 95-8.
8. De Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 hours continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997 ; 33 : 214-9.
9. Cunningham D, Pyrhönen S, James R, Punt C, Hickish T, Heikkila R, et al. A phase III multicenter randomized study of CPT-11 versus supportive care alone in patients with 5-FU-resistant metastatic colorectal cancer. Proc Am Soc Clin Oncol 1998 ; 17, A1 (abstract).
10. Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Germa-Lluch J, et al. A phase III multicenter randomized trial comparing CPT-11 to infusional 5-FU regimen in patients with advanced colorectal cancer after 5-FU. Proc Am Soc Clin Oncol 1998 ; 17 : A256.
11. Rougier P, Bugat E, Douillard J, Culine S, Suc E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997 ; 15 : 251-60.
12. Van Cutsem E, Cunningham D, Ten Bokkel Huinink W, Dirix L, Punt C, Alexopoulos C, et al. Irinotecan (CPT-11) multicenter phase II study in patients with 5-FU resistant colorectal cancer. Ann Oncol 1996 ; 7 : 128.
13. Van Cutsem E, Cunningham D, Ten Bokkel Huinink W, Punt C, Alexopoulos C, Dirix L, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-FU. Eur J Cancer (submitted).
14. Graf W, Påhlman L, Bergström R, Glimelius B. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 1994 ; 70 : 559-63.
15. Glimelius B, Hoffman K, Graf W, Påhlman L, Sjoden PO. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 1994 ; 73 : 556-62.
16. Van Cutsem E, Rougier P, Droz JP, Marty M, Bleiberg H. Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5-FU. Proc Am Soc Clin Oncol 1997 ; 16 : A950.
17. Rothenberg M, Eckhardt J, Kuhn J, Burris H, Nelson J, Hilsenbeck S, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996 ; 14 : 1128-35.
18. Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg R, Rubin J, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997 ; 15 : 2910-9.
19. Conti J, Kemeny NE, Saltz LB, Huang Y, Tong W, Chou T, et al. Irinotecan is an active agent in untreated patients with merastatic colorectal cancer. J Clin Oncol 1996 ; 14 : 709-15.
20. Van Hoff D, Rothenberg M, Pitot H, Elfring G, Mohrland J, Schaaf L, et al. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer : overall results of FDA-reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 1997 ; 16 : 228A.
21. De Gramont A, Figer A, Seymour M, Homerin M, Le Bail N, Cassidy J, et al. A randomised trial of leucovorin and 5-fluorouracil with or without oxaliplatin in advanced colorectal cancer. Proc Am Soc Clin Oncol 1998 ; 17 : 257a.
22. Van Cutsem E, Pozzo C, Starkhammer H, Dirix L, Terzoli E, Cognetti F, et al. A phase II study of irinotecan alternated with 5 days bolus of 5-fluorouracil and leucovorin in first line chemotherapy of metastatic colorectal cancer. Ann Oncol 1998 ; 9 : 1199-1204.